ArticleClinical, cosmetic and investigational dermatology2022
Sclerotherapy in Lymphatic Malformations with Intralesional Hemorrhage: A Retrospective Comparison with Non-Hemorrhagic Lymphatic Malformations.
Article in Clinical, cosmetic and investigational dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Laparoscopic polidocanol foam sclerotherapy for retroperitoneal lymphatic malformations in children: a single center retrospective study.BMC pediatrics · 2026Article
- Sclerotherapy combined with sirolimus for the treatment of complex cervicofacial lymphatic malformations in infants: avoiding the need for tracheostomy.Journal of neurointerventional surgery · 2026Article
- Case Report: Lymphatic malformation in a paediatric patient with a 7-year follow-Up.Frontiers in pediatrics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the outcomes of sclerotherapy with bleomycin and lauromacrogol between lymphatic malformations (LM) with and without intralesional hemorrhage and identify the factors affecting the outcomes of LM with hemorrhage. Patients and Methods: This retrospective study examined patients with LM who underwent sclerotherapy with bleomycin and lauromacrogol between January 2019 and December 2021. Regression models were used to analyze the factors associated with the outcomes of LM with hemorrhage. Results: 52 patients were included in the study, including 26 with intralesional hemorrhage. Masses with bluish skin ( Conclusion: Sclerotherapy with bleomycin and lauromacrogol is effective and safe for LM with hemorrhage. An increased number of injections for patients with hemorrhage was associated with similar efficacy for those without hemorrhage and similar relapse rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.